Showing results (5501-5510 of 5,703) with videos related to

Sort By:
Pageof 571
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
The Oncologist|December 5, 2025
Neoadjuvant TRK Inhibitors versus Chemotherapy in Advanced NTRK Fusion-Positive Sarcomas: A Real-World Evidence AnalysisFuyi Zhu, Haiyan Cheng, Yali Han, et al.
The Oncologist|January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL studySimona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
The Oncologist|January 11, 2026
Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitorsRosalba Torrisi, Federica Giugliano, Laura Giordano, et al.
The Oncologist|November 25, 2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastasesNoam Savion-Gaiger, Bryden Considine, Nitzan Hasson, et al.
The Oncologist|November 20, 2025
Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDXKuei-Ting Chen, Vidyalakshmi Sethunath, Ericka Ebot, et al.
The Oncologist|November 17, 2025
Long-term survival and prognostic factors after repeated metastasectomies in metastatic colorectal cancer: a 15-years retrospective studyGiovanni Trovato, Francesco Schietroma, Laura Chiofalo, et al.
The Oncologist|November 17, 2025
Central nervous system involvement-positive disease in consolidation/maintenance stage is a poor prognostic factor in pediatric T-cell acute lymphoblastic leukemia: a Chinese single-center reportXiaoming Liu, Yao Zou, Ye Guo, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Pageof 571